Clinical Context
A typical patient is an adult with relapsed or refractory multiple myeloma who qualifies for treatment with talquetamab-tgvs, a bispecific monoclonal antibody targeting GPRC5D and CD3. The patient presents to an outpatient oncology infusion center for administration of J3055 (injection, talquetamab-tgvs, 0.25 mg) as part of a prescribed dosing regimen after prior evaluation by the treating hematologist/oncologist. Prior to dosing, the clinical workflow includes verification of the order, weight and vital signs assessment, review of recent laboratory results (complete blood count, hepatic and renal panels), assessment for active infections, and documentation of prior therapies and response. Infusion center nursing performs drug preparation per manufacturer guidance, checks for patient-specific contraindications (including pregnancy status), and establishes IV access or performs subcutaneous injection as indicated by the product specification.
During administration, nursing monitors for infusion- or injection-related reactions and cytokine release syndrome, documents medications given for prophylaxis or treatment (e.g., antipyretics, antihistamines, corticosteroids), and records start and stop times and lot number/expiration of the biologic. The prescribing hematologist/oncologist evaluates the patient post-administration for adverse events and adjusts future dosing or supportive care as indicated. Billing for the administered drug uses J3055 per 0.25 mg increment, with appropriate modifier reporting for site of service, patient status, and drug disposition when required.